Sciatic nerve blockade and local tissue response to bupivacaine HCl in rats
Animal study · Adult male Sprague-Dawley rats, 310–420 g; sciatic nerve block [1]
Single injections of unencapsulated HCl produced thermal sensory blockade, with muscle injury and inflammation on subsequent histology. The higher HCl concentration also increased contralateral thermal latency. No nerve-structure changes were detected by the study’s qualitative histology. Behavioral testing and tissue harvesting are retained together as one model study, with their different sample sizes explicit.
| Endpoint | Reported result | Reference |
|---|---|---|
| Thermal nociceptive block duration; return of withdrawal latency from above to 7 s | Median (25th–75th percentiles), minutes 0.5% HCl: 120 (120–165); 1.31% HCl: 210 (180–240); Exparel: 240 (240–240); n=10 per group | [1] |
| Contralateral paw withdrawal latency after 1.31% HCl versus baseline | Median (25th–75th percentiles), seconds Baseline 2.7 (2.3–3.1); peak 4.4 (3.4–4.8); P=0.005 | [1] |
| Local muscle injury at day 4 and day 14 | Median (25th–75th percentiles), ordinal score 0–6 0.5% HCl: day 4, 3.0 (3.0–4.0); day 14, 1.5 (1.0–2.0). 1.31% HCl: day 4, 5.0 (3.8–5.0); day 14, 3.0 (1.8–4.0). n=6 per group per time point. | [1] |
| Axonal density, myelin structure and perineural tissue at 4 and 14 days | Qualitative histology No significant structural changes observed in any treatment group; quantitative neurotoxicity analysis not performed | [1] |
Conditions shared by the study groups
- Route
- Injection at sciatic nerve
- Frequency
- Once
- Treatment course
- Single administration; histology at days 4 and 14
| Group / dose | Comparator | Observed result | Reference |
|---|---|---|---|
| 0.5% (w/v) bupivacaine HCl 0.6 mL; approximately 10 mg/kg, as reported | Other formulation groups; uninjected contralateral limb for systemic-effect testing; normal uninjected nerve illustrated in Figure 5D. No saline-injection histology group described. | Median thermal block 120 (120–165) min; muscle injury detected; no significant contralateral deficit (P=0.31). | [1] |
| 1.31% (w/v) bupivacaine HCl 0.6 mL; approximately 25 mg/kg, as reported | Other formulation groups; uninjected contralateral limb for systemic-effect testing; normal uninjected nerve illustrated in Figure 5D. No saline-injection histology group described. | Median thermal block 210 (180–240) min; muscle injury detected; contralateral latency increased (P=0.005). | [1] |
| Exparel formulation comparator 0.6 mL; approximately 25 mg/kg total bupivacaine, as reported | Other formulation groups; uninjected contralateral limb for systemic-effect testing; normal uninjected nerve illustrated in Figure 5D. No saline-injection histology group described. | Median thermal block 240 (240–240) min; myotoxicity scores 2.5 (1.0–3.3) at day 4 and 1.0 (1.0–2.0) at day 14; n=6/group/time for histology. | [1] |
- 0.5% (w/v) bupivacaine HCl
- Model: Adult male Sprague-Dawley rats, 310–420 g; sciatic nerve block
- Reported limits: Behavioral n=10/group; histology n=6/group/time. The cohort overlap is not stated. No matched saline-injection histology control.
- 1.31% (w/v) bupivacaine HCl
- Model: Adult male Sprague-Dawley rats, 310–420 g; sciatic nerve block
- Reported limits: Behavioral n=10/group; histology n=6/group/time. The cohort overlap is not stated. No matched saline-injection histology control.
- Exparel formulation comparator
- Model: Adult male Sprague-Dawley rats, 310–420 g; sciatic nerve block
- Vehicle: 0.9% sodium chloride suspension
- Reported limits: Behavioral n=10/group; histology n=6/group/time. The cohort overlap is not stated. No matched saline-injection histology control.
Methods and source locations
Compound reported in the paper: Bupivacaine hydrochloride; Compound label in the paper: Unencapsulated HCl solutions; Exparel is a separate formulation comparator
Rat HCl solution experiments only; no clinical dosing recommendation, salt conversion or Adooq lot validation.
Materials and Methods: Materials, Animal Care, Sciatic Blockade Technique, Assessment of Nerve Blockade, Tissue Harvesting and Histology, Statistical Analysis; Results: Duration of sciatic nerve blockade; Systemic distribution of bupivacaine; Tissue Reaction; Tables 1 and 2; Figures 4 and 5
Thermal nociceptive block duration; return of withdrawal latency from above to 7 s: 56°C hotplate; 12 s safety cutoff; uninjected limb assesses systemic effects. Planned comparisons were Exparel versus each HCl group (P=0.001 and 0.013 respectively); no HCl-versus-HCl P value adopted. — Methods: Assessment of Nerve Blockade and Statistical Analysis; Results: Duration of sciatic nerve blockade; Table 1
Contralateral paw withdrawal latency after 1.31% HCl versus baseline: Uninjected limb thermal testing used as a functional proxy for systemic distribution, not a plasma concentration assay. No significant deficits detected with 0.5% HCl (P=0.31) or Exparel (P=1.00). — Results: Systemic distribution of bupivacaine; Methods: Assessment of Nerve Blockade
Local muscle injury at day 4 and day 14: H&E-stained muscle; scoring based on depth/extent of nuclear internalization and regeneration. Table 2 P values compare each HCl group with Exparel, not the two HCl groups directly. — Methods: Tissue Harvesting and Histology; Results: Tissue Reaction; Table 2; Figure 4B,C,E,F,I,J,L,M
Axonal density, myelin structure and perineural tissue at 4 and 14 days: Epon-embedded nerve, 0.5 μm toluidine-blue sections; Figure 5 includes normal uninjected nerve. This is not proof of absence of all neurotoxicity. — Methods: Tissue Harvesting and Histology; Results: Tissue Reaction, final paragraph; Figure 5A–D and caption
0.5% (w/v) bupivacaine HCl · Methods: Sciatic Blockade Technique; Results: Duration of sciatic nerve blockade, Systemic distribution, Tissue Reaction; Tables 1 and 2; Figure 5
1.31% (w/v) bupivacaine HCl · Methods: Sciatic Blockade Technique; Results: Duration of sciatic nerve blockade, Systemic distribution, Tissue Reaction; Tables 1 and 2; Figure 5
Exparel formulation comparator · Methods: Sciatic Blockade Technique; Results: Duration of sciatic nerve blockade, Systemic distribution, Tissue Reaction; Tables 1 and 2; Figure 5